CSL (HAM:CSJ) Valuation Rank


HAM:CSJ CSL Ltd HAM:CSJ
73 GF Score
Price €70.36
GF Value €171.51
Valuation Significantly Undervalued
! 7 Warning Signs
View Full Analysis

What is CSL Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

CSL Valuation Rank Related Terms

HAM:CSJ
73GF Score
CSL Ltd HAM:CSJ
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is CSL (HAM:CSJ) Overvalued in 2026?

Based on GuruFocus' analysis, CSL stock appears to be undervalued. The current stock price of €70.36 is trading 59% below its estimated GF Value™ of €171.51. GuruFocus considers CSL to be Significantly Undervalued.

Key valuation signals for HAM:CSJ:

  • Valuation Rank:
  • GF Value™: €171.51 vs. price of €70.36 (59% below fair value)
  • GF Score™: 73/100 with 7 warning signs

No single metric tells the full story. See the HAM:CSJ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CSL Business Description

Address 655 Elizabeth Street, Melbourne, VIC, AUS, 3000
CSL is one of the largest global biotech companies and has three main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders, and neurological indications. CSL Seqirus is the world's second-largest influenza vaccination business and was acquired in fiscal 2016. CSL Vifor is an iron deficiency and nephrology business and was acquired in fiscal 2023. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.
73GF Score

Get the complete analysis for HAM:CSJ

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€70.36
Price
€171.51
GF Value